TD Cowen raised the firm’s price target on NeoGenomics (NEO) to $12 from $10 and keeps a Buy rating on the shares after hosting meetings with management. The firm left more constructive on NeoGenomics’s new product launches, saying MolDX reimbursement remains the “final gate” for a 2026 ramp.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics Buy Rating: Strategic Product Launches and Management Changes Drive Growth Potential
- NeoGenomics price target raised to $11 from $6.50 at Stephens
- Dell reports ‘beat and raise,’ Caterpillar sees big tariff impacts: Morning Buzz
- NeoGenomics’ Legal Victory and Market Potential Boosts Buy Rating
- NeoGenomics announces court ruling in its favor in lawsuit against Natera